Reading that it would seem the P value directly correlates with the Clinical trials Safety. As they have noted that there are no toxicity in the first trial they can adopt a higher p value and reduce the patients. (because peoples health is solely because of the cancer and not a biproduct of the treatment)
Or maybe I'm wrong.. Just my interpretation
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.0¢ |
Change
0.000(0.00%) |
Mkt cap ! n/a | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| IMU (ASX) Chart |
Day chart unavailable